SAMSUNG PLAYS DOWN AI BUBBLE FEARS:
TODAY'S AI INVESTMENT IS NOT SPECULATION, BUT ACTUAL TANGIBLE DEMAND
NEOCLOUDS ARE ONLY ABOUT 8% OF THE OVERALL MARKET
WE DO NOT EXPECT NEOCLOUD CONCERNS TO POSE A SIGNIFICANT THREAT TO THE BROADER AI GROWTH TRAJECTORY
THE CHIP SHORTAGE WILL PERSIST FOR THE FORESEEABLE FUTURE
SAMSUNG PLANS A "SUBSTANTIAL" BUYBACK, WITH DETAILS IN JANUARY
Samsung Biologics' $2 billion rights offering was oversubscribed more than five times, drawing bids for 11.9 million shares against 2.3 million offered. The proceeds help fund its acquisition of PolyPeptide, per Dow Jones.